Results 11 to 20 of about 6,218 (156)

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue.
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)

Brazilian Journal of Infectious Diseases, 2023
Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García, Francesco Marchesi, Livio Pagano, Oliver A. Cornely   +3 more
doaj   +1 more source

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report

Viruses, 2023
Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this ...
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Lavinia Maria Saraca, Luca Capogrossi, Maria Bruna Pasticci, Daniela Francisci   +9 more
doaj   +1 more source

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Frontiers in Pharmacology, 2023
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives ...
Jiayue Lu, Hong Cai, Yujun Hao, Zhang Lin, Shang Liu, Yaping Zhan, Li Ding, Meilan Huang, Zhenyuan Li, Lan Xu, Xiujuan Yan, Li Yang, He Zhang, Wei Zhang, Li Zhao, Junli Zhao, Ting Wang, Leyi Gu   +17 more
doaj   +1 more source

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19

Infection and Drug Resistance, 2023
Cheng-Yi Hu,1 Wen-Shuai Cui,1 Yi Lei,1 Yu-Wen Tang,1 Yan-Yan Zhang,1 Qi-Min Su,1 Fang Peng,2 Yun-Fei Zeng,1 Jia-Lin Song,1 Cheng-Na Luo,1 Yan Zhou,1 Xin-Yan Li,1 Zhu-Xiang Zhao1 1Department of Infectious Diseases, Guangzhou First People’s Hospital ...
Hu CY, Cui WS, Lei Y, Tang YW, Zhang YY, Su QM, Peng F, Zeng YF, Song JL, Luo CN, Zhou Y, Li XY, Zhao ZX   +12 more
doaj